Detalles de la búsqueda
1.
Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Diabetes Obes Metab
; 25(7): 1874-1882, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36872068
2.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Diabetes Obes Metab
; 25(6): 1646-1657, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36782093
3.
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Neuroendocrinology
; 112(3): 298-310, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-33940581
4.
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
Ann Intern Med
; 174(8): 1065-1072, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152828
5.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
Diabetes Obes Metab
; 23(12): 2632-2642, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34338408
6.
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
N Engl J Med
; 377(24): 2337-2348, 2017 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28899222
7.
Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Diabetes Obes Metab
; 21(11): 2440-2449, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264767
8.
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin.
Diabetes Technol Ther
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38441906
9.
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
Clin J Am Soc Nephrol
; 19(5): 557-564, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38277468
10.
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
J Am Coll Cardiol
; 82(19): 1842-1851, 2023 11 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914514
11.
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
Diabetes Care
; 45(9): 2118-2126, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35817022
12.
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
J Gastrointest Cancer
; 52(1): 212-221, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32146619
13.
Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Diabetes Technol Ther
; 23(1): 70-77, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32721228
14.
Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Diabetes Technol Ther
; 23(1): 59-69, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32640846
15.
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
J Clin Endocrinol Metab
; 105(4)2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31837264
16.
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Diabetes Care
; 43(11): 2713-2720, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928957
17.
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Diabetes Care
; 42(5): 919-930, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30833371
18.
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
J Patient Rep Outcomes
; 3(1): 64, 2019 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655936
19.
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.
Eur J Heart Fail
; 26(4): 1093-1095, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38629597
20.
The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3.
Diabetes Care
; 46(7): e133-e135, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37172207